#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Follicular lymphoma stage II Hereditary ataxia Gastrointestinal stromal tumour Astrocytoma Hodgkin's disease refractory Autoimmune haemolytic anaemia Biliary cancer metastatic Leukocyte adhesion deficiency Anal cancer Mantle cell lymphoma recurrent Neurofibroma Stress cardiomyopathy Shprintzen-Goldberg syndrome Duchenne muscular dystrophy gene carrier Primary biliary cholangitis More trials…

    Learn about Rare Diseases

    Alport’s syndrome – Basic Information Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Pleural mesothelioma malignant – Treatment KBG syndrome – Treatment Niemann-Pick disease – Treatment Paroxysmal nocturnal haemoglobinuria – Life with Disease X-linked lymphoproliferative syndrome – Basic Information Anaplastic thyroid cancer Uterine leiomyosarcoma Prolymphocytic leukaemia – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Povidone Ocrelizumab Sibeprenlimab Ripasudil Bromocriptine Raltegravir Zipalertinib M2Rlab Stiripentol Rasagiline Imsidolimab Coffee Charcoal Satoreotide Tetraxetan Domvanalimab Darolutamide Bupropion Hydrochloride Amoxicillin Trihydrate Losmapimod Reparixin Isaralgagene Civaparvovec More therapies…

    Learn about Your Condition

    Neuropathic arthropathy Obsessive-compulsive disorder Juvenile spondyloarthritis Cardiac failure Alveolar rhabdomyosarcoma Hydrocele Rhinitis allergic Nephrotic syndrome Myxoid liposarcoma Aplasia pure red cell Uveitis Pharyngeal cancer stage II Cataract Hepatic adenoma Choroidal neovascularisation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Docetaxel
    • Tislelizumab
    Belgium France Germany Greece Hungary Italy +3

  • Study comparing cetuximab with chemotherapy versus bevacizumab with chemotherapy in patients with advanced colorectal cancer who have wild-type RAS and right-sided tumors

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Bevacizumab
    • Capecitabine
    • Cetuximab
    Germany Italy Spain

  • Study of obinutuzumab to reduce PLA2R antibodies in patients with primary membranous nephropathy

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Glomerulonephritis membranous
    Investigated Drugs:
    • Obinutuzumab
    The Netherlands

  • Study of cannabidiol to reduce self-injurious behavior in children and adolescents with severe neurodevelopmental disorders

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Cannabidiol
    France

  • First study of TTX-381 gene therapy safety in patients with eye problems caused by CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2)

    Not yet recruiting

    2 1 1
    Investigated Drugs:
    • TTX-381
    Germany

  • Study of brentuximab vedotin for maintenance therapy in patients with cutaneous T-cell lymphoma after stem cell transplant

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Cutaneous T-cell lymphoma
    Investigated Drugs:
    • Brentuximab Vedotin
    France
Previous Page
1 … 788 789 790 791 792 … 1,673
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!